CARMAT Secures $11.5 Million Funding for Breakthrough Artificial Heart Technology

CARMAT, the innovative French MedTech company behind the groundbreaking Aeson® artificial heart, has successfully secured €11.5 million in funding to bolster its mission of transforming cardiac care for patients suffering from end-stage biventricular heart failure. Founded in 2008 and headquartered in the Paris region, CARMAT has developed the world's first physiological artificial heart, designed to be highly hemocompatible, pulsatile, and self-regulated. With the growing demand for heart transplants outpacing the availability of human grafts, Aeson® offers a vital therapeutic alternative, aiming to save thousands of lives annually. The newly acquired funds will be instrumental in furthering CARMAT's research and development efforts, enabling the company to enhance the Aeson® device and expand its market presence. Currently available as a bridge to transplant in the European Union and other CE-mark-recognizing countries, Aeson® is also undergoing evaluation in the United States through an Early Feasibility Study (EFS). This additional financing will not only support ongoing clinical studies but will also facilitate production scalability and the enhancement of the product’s user-friendly external power supply system, allowing patients improved mobility and quality of life. CARMAT prides itself on its expert team of over 200 professionals dedicated to pioneering life-saving technologies, and this funding underscores the healthcare community's growing confidence in their vision. As the company navigates its next steps, the CARMAT team is excited to move closer to making Aeson® the go-to alternative for heart transplant patients worldwide.